Press Releases

BETHESDA, MD, June 4, 2014 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the Jefferies 2014 Global Healthcare Conference, which is being held in New York. NW Bio’s presentation will take place on Wednesday, June 4, at 2:00 p.m. EDT in Ballroom 5 at the Grand Hyatt in New York... Read More

Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May 29, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, refuted the latest blatantly false and misleading statements made by Adam Feuerstein, in an article on Tuesday, May... Read More

BETHESDA, MD., May 27, 2014 / PRNewswire/ – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio) announced today that the Company will host a conference call and webcast  with CEO Linda Powers today, May 27, 2014, at 4:30 p.m. Eastern time to review the early results of the Phase I/II DCVax®-Direct Trial announced this morning and answer questions. Participants must register in order to participate in the conference call.  There are three... Read More

Initial Responses Seen Before Patients Have Completed Treatments; Preliminary Signs of Cancer Cell Death, Tumor Shrinkage & Stabilization of Disease BETHESDA, Md., May 27, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a summary of initial data to date in its ongoing Phase I/II clinical trial of DCVax-Direct... Read More

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression,... Read More